Total Marrow with Lymphoid Irradiation (TMLI) as a conditioning regimen using VMAT technique: Planning and dosimetry validation

Reena Devi Phurailatpam,^a Kishore Joshi^a, Supratip Kapat^a, Ann Christy Saju^b, Jayant S. Goda^a, Chandrashekhar Tambe^c, Rajesh A Kinhikar^c, Siddharth S Laskar^b ^a Department of Radiation Oncology, ACTREC, Tata Memorial Centre, Homi Bhabha National institute, Kharghar, Navi Mumbai ^b Department of Radiation Oncology, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National institute, Mumbai,^c Department of Medical Physics, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National institute, Mumbai * Corresponding author: reena.ph@gmail.com

Background and Objective

To study the planning and dosimetric feasibility of implementing TMLI (Total Marrow with lymphoid Irradiation) using Volumetric modulated arc therapy (VMAT) as a conditioning for bone marrow transplant.

Methods

- > Four patients who were planned to receive cyclophosphamide- TMLI based conditioning for allogenic transplant were accrued in the present study after institutional ethics committee approval.
- > VMAT plans on TrueBeam Linac (Varian Medical Systems, USA) using Eclipse treatment planning system (TPS version 13.5).
- > Dosimetrically validated using Lithium fluoride thermoluminescent dosimeters (LiF chambers and ArcCHECK phantom (M/S SUN NUCLEAR CORPORATION).
- \succ PTV-TMLI encompassed the entire CTV TMI and CTV TLI and the sanctuary sites of brain and Testis. Organs at risk (OAR) to be spared : lungs, heart, liver, kidneys, eyes, oral cavity, thyroid, parotids and bowels.
- \blacktriangleright Dose prescription was 13.2Gy/8#, 1.65 Gy delivered twice daily.
- \succ VMAT plans were generated using 8 overlapping 360° coplanar arcs optimized simultaneously. 6MV photon FF at dose rate 600MU/min.(Fig 1)
- \succ The isocentre was placed at the overlapping area between the two adjacent arcs which was 4 cm and to eliminate the uncertainty in matching the two planes. Four isocentres were selected to encompass the entire PTV with asymmetric jaw settings. The collimator was set to 90° and field width (Y direction) of 40 cm, and field length (X direction, i.e. the direction of movement of leaves) ranged from 15 to 16 cm to allow maximal modulation. (1)

<u>References</u>

[1] Mancosu P, Navarria P, Castagna L, et al. Anatomy driven optimization strategy for total marrow irradiation with a volumetric modulated arc therapy technique. J Appl Clin Med Phys. 2012;13(1):3653. Published 2012 Jan 5. doi:10.1120/jacmp.v13i1.3653 [2] Symons, Kirsty; Morrison, Colm; Parry, Jason; Woodings, Simon; Zissiadis, Yvonne (2018). Volumetric modulated arc therapy for total body irradiation: A feasibility study using Pinnacle ³ treatment planning system and Elekta Agility[™] linac. Journal of Applied Clinical Medical Physics,.doi:10.1002/acm2.12257

TLD), Ionization

Dosimetric validation

TLD and Ionization chambers : A thorax phantom and a rectangular phantom(density 1.03 g/cm3) were strapped together to make a phantom of length 100cm.(Fig 2) 25 TLDs along with 3 ionization chambers(0.125cc PTW) were placed at different places of the phantom.

<u>Planar dose validation</u>: Arc check phantom was used for planar dose verification.(2) It is a commercial diode array designed specifically for rotational measurements. Planar dose for each arc of individual plans were verified. Dose distributions were analyzed using gamma criteria of 3% dose and 3 mm distance to agreement

Results and Discussion

The mean volume of PTV encompassed by 95 % Isodose line was 92 % of the PTV volume and D2 (mean dose of 2cc volume of PTV) was 104% of prescribed dose. Conformity and homogeneity index were 0.90 and 0.21 respectively. OAR doses are given

In the table 1.

Percentage variation in point dose measurements with Ionization chambers were found to be within 5%. The mean TLDs reading was within 7% of the TPS calculated dose. Planer dose verification was passed within 99% of gamma index with 3%-3 mm criteria. (Fig 3)

Conclusions: Although resource intensive, the favorable dosimetry of VMAT based TMLI and its validation using two independent methods makes this technique robust enough to potentially replace the conventional TBI technique with adequate PTV coverage and better OAR sparing effect.




Fig1. Dose distribution and Beam arrangement

OAR Right Eyeba Left Eyeba Oral cavit Lt Parotic Rt Parotic Thyroid Heart Left lung Right lung Liver Left Kidne Right Kidne Bowel

Table 1: OAR DOSES



	Mean Dose Gy(Std
	deviation)
all	7.95(1.13)
all	7.80(1.14)
.y	6.9(1.32)
b	7.27(0.77)
d	7.03(0.61)
	12.65(0.87)
	6.9(0.77)
	8.25(0.82)
g	8.63(0.95)
	9.01(1.01)
Эу	6.08(1.45)
еу	6.64(0.96)
	9.57(1.47)

Fig 2.100 cm Phantom for dosimetry With TLD and Ionization chambers

210 ¹ 240 ⁰ 270 ¹ 300 ⁰ 330 ¹ 0 ¹ 30 ¹ 60 ¹ 80	" 129" 150" 017 Out				511
		100 210 ⁴ 200 ⁹ 2	10, 30% 236, 0, 30, 46, 90, 730, 726,	cor Dat	
	• 131 performance				AL
	EL CLOBE			D/Oher	10.0
0-				lived .	
	19 54			Yest of the second	4
" HEALTHY AND				-18 14	
			100 - 100 - 100		
-12 -28 -24 -20 -16 -12 -8 -4 0 4 8 12 16	1 11 18 10			4	
Pavel51586 PHATOKERIpDED Waxand 20Ke 3026 M	1 9 74 -12 -28 -24 -25 -15 -12 -8 -4 5	-32-20-24-2	1-16-12 -8 -4 0 4 8 12 16 20 24 26 32 NaDEO Human 2014 20 32	Q Fer -12 -28 -24 -29 -	16-12 -8 -4 0 4 8 12 16 20 24
🖉 Deze 🖉 Nam 🖉 Zoon 🔯 Perle 🔄 Role - Cer	1785_0012206302717206392707210893000020146365350	HANATIKE C. D. C. Bar Man 22m	Nik Nie Or		A STRUTTER STREEMER SHE IS
0		59 J			
9	AND AND ADDRESS OF ADDRESS	# 190 # 191	1 COLUMN	R2-240.000	
6	9 8.307 0000777	# -24 # 111	()))))))))))))))))))		
1	100000000000000000000000000000000000000	#171 #17)		20
	WARDEN CONTRACTOR		4	20.05 301	10.0
	1000	1	4		
			4 1. 10 1. 1981		10
-4			10.00 M 10.00		81
000/ 24	aamma	inday wi	th 20/ 1	2 mm	oritoria
33 /0 UI	<mark>i gamma</mark> i				Unteric
prov.	11 - 11	* <u>)</u>		0 Sel = SeC	
	+ Set = Se2	8 B 6		-	and the second
		and the second se	4-		
A.M.		مورد و مقاله	and a second and a second	and a second and	and a state of the
	-	www.	and a second	and the second s	and a state of the
			and the second s	I II II	NI 31 31
	* 11 ⁰ 11 ⁰ 00 00				N 20 21
1 20° 20° 20° 20° 20° 40° 40° 40° 40° 40° 40° 40° 40° 40° 4	* 11 ⁰ 11 ⁰ 00 00				- 10 30 30
					N 30 81
				CALOBLE Ven D	N N N
			310 110 111 40 210 300 10 10 10 10	Cliffer Van D Yan D	
			310 110 111 01 210 310 40 40 10 120 120 210 310 310 10 10 10 10	CALOBLE Ven D	
			210 MIN 200 - 0 MIN 40 MIN 200 - 200		
2 3 3 3 3 3 3 3 3 3 3 3 3 3		4 8 12 16 22 24 28 31 HTPare/CS1908/Productionus	200 - 100 - 100 - 40 200 - 100 - 100 - 40 200 - 200 ² - 20		
X		4 8 12 16 20 24 28 33 HPart/Childer/Problems	Marchillor Measured 22 May 2020 Alle		10 20 20 10 20 20 10 20 20 10 20 10 10 10 10 10 10 10 10 10 1
		4 8 12 16 22 24 28 31 HTPare/CS1908/Productionus	Marchillor Measured 22 May 2020 Alle		
		4 8 12 16 22 24 28 31 HTPare/CS1908/Productionus	Marchillor Measured 22 May 2020 Alle		
		4 8 12 16 22 24 28 31 HTPare/CS1908/Productionus	Marchillor Measured 22 May 2020 Alle		
		4 8 12 16 22 24 28 31 HTPare/CS1908/Productionus	Marchillor Measured 22 May 2020 Alle		
		4 8 12 16 22 24 28 31 HTPare/CS1908/Productionus	Marchillor Measured 22 May 2020 Alle		
		4 8 12 16 22 24 28 31 HTPare/CS1908/Productionus	MacDitto Hearing United In 1997		
		4 8 12 16 22 24 28 31 HTPare/CS1908/Productionus	Ng Oli O Hanand Line Julian Ju a Thin The De J 6 3 	Image: Second	
			Macdito menalti ve pilitar e Thie The De	Image: Second	maanse en
			Macdito menalti ve pilitar e Thie The De		an access of an access of a second data of
			Macdito menalti ve pilitar e Thie The De	Image: Second	an access of an access of a second data of
			MacDitto Second Live (Distance)		an access of an access of a second data of

Fig 3.Dose analysis ARC CHECK